PartnershipAug 11, 2026, 07:32 AM
C4 Therapeutics Secures Roche DAC Partnership with $20M Upfront, $1B+ Milestones
AI Summary
C4 Therapeutics announced a new collaboration and license agreement with Roche to develop degrader-antibody conjugates (DACs) for oncology targets. The agreement includes an upfront payment of $20.0 million and potential milestone payments exceeding $1.0 billion. For the six months ended June 30, 2026, the company reported a net loss of $48.8 million, an improvement from $52.3 million in the prior year period. C4 Therapeutics also confirmed its cash, cash equivalents, and marketable securities of $300.4 million are sufficient to fund operations for at least the next twelve months.
Key Highlights
- Entered new collaboration with Roche for degrader-antibody conjugates (DACs).
- Received $20.0 million upfront payment from Roche.
- Eligible for over $1.0 billion in potential milestone payments from Roche.
- Net loss for six months ended June 30, 2026, was $(48.8) million.
- Net loss per share improved to $(0.38) for the six months.
- Cash, cash equivalents, and marketable securities totaled $300.4 million.
- Existing funds sufficient for at least the next 12 months of operations.
Price Impact
More from CCCC